Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Interest & Investment Income (2023 - 2025)

Historic Interest & Investment Income for Ernexa Therapeutics (ERNA) over the last 3 years, with Q3 2025 value amounting to $31000.0.

  • Ernexa Therapeutics' Interest & Investment Income rose 10183.87% to $31000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year increase of 917.0%. This contributed to the annual value of -$6.8 million for FY2024, which is 99967.43% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Interest & Investment Income of $31000.0 as of Q3 2025, which was up 10183.87% from $5000.0 recorded in Q1 2025.
  • Ernexa Therapeutics' 5-year Interest & Investment Income high stood at $31000.0 for Q3 2025, and its period low was -$3.5 million during Q4 2024.
  • Moreover, its 3-year median value for Interest & Investment Income was -$319500.0 (2023), whereas its average is -$733000.0.
  • In the last 5 years, Ernexa Therapeutics' Interest & Investment Income tumbled by 7870000.0% in 2024 and then surged by 10183.87% in 2025.
  • Over the past 3 years, Ernexa Therapeutics' Interest & Investment Income (Quarter) stood at -$526000.0 in 2023, then crashed by 562.17% to -$3.5 million in 2024, then soared by 100.89% to $31000.0 in 2025.
  • Its Interest & Investment Income stands at $31000.0 for Q3 2025, versus $5000.0 for Q1 2025 and -$3.5 million for Q4 2024.